ATE98125T1 - COMPOSITIONS OF ESSENTIAL FATTY ACIDS AND THERAPY. - Google Patents

COMPOSITIONS OF ESSENTIAL FATTY ACIDS AND THERAPY.

Info

Publication number
ATE98125T1
ATE98125T1 AT91300234T AT91300234T ATE98125T1 AT E98125 T1 ATE98125 T1 AT E98125T1 AT 91300234 T AT91300234 T AT 91300234T AT 91300234 T AT91300234 T AT 91300234T AT E98125 T1 ATE98125 T1 AT E98125T1
Authority
AT
Austria
Prior art keywords
therapy
compositions
fatty acids
essential fatty
bioavailable
Prior art date
Application number
AT91300234T
Other languages
German (de)
Inventor
David Frederick Horrobin
Frank Corrigan
Original Assignee
Scotia Holdings Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotia Holdings Plc filed Critical Scotia Holdings Plc
Application granted granted Critical
Publication of ATE98125T1 publication Critical patent/ATE98125T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A pharmaceutical composition of GLA or DGLA and bioavailable selenium, optionally also with an 18:4 or higher n-3 EFA and/or bioavailable zinc.
AT91300234T 1990-01-18 1991-01-14 COMPOSITIONS OF ESSENTIAL FATTY ACIDS AND THERAPY. ATE98125T1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909001121A GB9001121D0 (en) 1990-01-18 1990-01-18 Efa compositions and therapy

Publications (1)

Publication Number Publication Date
ATE98125T1 true ATE98125T1 (en) 1993-12-15

Family

ID=10669492

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91300234T ATE98125T1 (en) 1990-01-18 1991-01-14 COMPOSITIONS OF ESSENTIAL FATTY ACIDS AND THERAPY.

Country Status (14)

Country Link
US (1) US5116624A (en)
EP (1) EP0440341B1 (en)
JP (1) JP3008213B2 (en)
AT (1) ATE98125T1 (en)
AU (1) AU638525B2 (en)
CA (1) CA2033823C (en)
DE (1) DE69100724T2 (en)
DK (1) DK0440341T3 (en)
ES (1) ES2060290T3 (en)
GB (1) GB9001121D0 (en)
HK (1) HK74994A (en)
IE (1) IE67622B1 (en)
NZ (1) NZ236744A (en)
ZA (1) ZA91183B (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US5407957A (en) * 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
GB9111900D0 (en) * 1991-06-03 1991-07-24 Efamol Holdings Fatty acid compositions
GB9112052D0 (en) * 1991-06-05 1991-07-24 Efamol Holdings Fatty acid treatment
EP0626856A1 (en) * 1992-02-19 1994-12-07 Colby Corporation Limited Pharmaceutical compositions and their use for treating zinc deficient disorders
US20050027004A1 (en) * 1993-06-09 2005-02-03 Martek Biosciences Corporation Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
GB9403855D0 (en) * 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
WO1997044026A1 (en) * 1996-05-22 1997-11-27 Neuromedica, Inc. Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
TR199900786T2 (en) * 1996-10-11 1999-07-21 Scotia Holdings Plc Pharmaceutical compositions containing Eykoza penta enoic acid and/or stearidonic acid.
WO1998048788A1 (en) * 1997-04-29 1998-11-05 Scotia Holdings Plc Treatment of depression and anxiety using docosahexaenoic acid or natural antioxidants
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US6225444B1 (en) 1998-02-10 2001-05-01 Protarga, Inc. Neuroprotective peptides and uses thereof
FR2774596B1 (en) * 1998-02-11 2000-03-17 Rhone Poulenc Rorer Sa USE OF SELENATED COMPOUNDS IN THE PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE
US7235583B1 (en) * 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
US6258846B1 (en) * 1999-06-01 2001-07-10 Drugtech Corporation Nutritional supplements
US7112609B2 (en) * 1999-06-01 2006-09-26 Drugtech Corporation Nutritional supplements
FR2816211B1 (en) * 2000-11-08 2005-04-01 Brif NEW DIETETIC AND / OR COSMETIC COMPOSITIONS FOR IMPROVING MUCOUS DROUGHT
WO2002076402A2 (en) * 2001-03-23 2002-10-03 Protarga, Inc. Fatty amine drug conjugates
ATE556706T1 (en) * 2001-03-23 2012-05-15 Luitpold Pharm Inc FAT ALCOHOL-DRUG CONJUGATES
US20040076695A1 (en) 2002-07-08 2004-04-22 Advanced Vision Research EPA and DHA enriched omega-3 supplement for the treatment of dry eye, meibomianitis and xerostomia
DE10305138A1 (en) * 2003-02-07 2004-08-26 Axxima Pharmaceuticals Ag Composition, useful for the prophylaxis/treatment of hepatitis C virus infection and/or associated diseases, comprises an agent e.g. selenium, all trans retinoic acid or 9-cis retinoic acid
US20060292217A1 (en) * 2005-06-03 2006-12-28 Schmidt Robbin D Nutritional supplement and soft gelatin capsule delivery system
NZ540958A (en) 2005-06-27 2007-11-30 Agres Ltd Veterinary formulation for injectable administration of selenomethionine for production of selenium-rich foods
US8871715B2 (en) * 2005-10-14 2014-10-28 Alltech, Inc. Use of selenium compounds, especially selenium yeasts for altering cognitive function
AU2005227420B2 (en) * 2005-10-14 2013-05-09 Alltech, Inc. Method and compositions for altering cell function
US8865763B2 (en) * 2005-10-14 2014-10-21 Alltech, Inc. Methods and compositions for altering cell function
US20080004255A1 (en) * 2005-10-14 2008-01-03 Alltech, Inc. Methods and compositions for altering cell function
US20100247679A1 (en) * 2006-04-24 2010-09-30 Alltech, Inc. Methods and compositions for altering cell function
EP2211881A4 (en) * 2007-11-01 2012-01-04 Wake Forest University School Of Medicine Compositions and methods for prevention and treatment of mammalian diseases
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
WO2009133586A1 (en) * 2008-04-28 2009-11-05 有限会社アンティアンティ Remedy for alzheimer's disease
AU2011315532B2 (en) * 2010-10-12 2015-02-05 Vifor Sa Novel omega-3 and omega-6 fatty acid compositions and uses thereof
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US20120252888A1 (en) * 2011-03-29 2012-10-04 Palupa Medical Ltd. Compositions and Methods for Treating Neurologic Disorders
JP2016023163A (en) * 2014-07-22 2016-02-08 出光興産株式会社 AGENT FOR REDUCING OXIDATIVE STRESS ON NERVE CELLS COMPRISING γ-LINOLENIC ACID

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1082624A (en) 1965-02-26 1967-09-06 Calmic Ltd Improvements in or relating to therapeutically active compounds
US4273763A (en) * 1978-01-23 1981-06-16 Efamol Limited Pharmaceutical and dietary compositions
IE47777B1 (en) 1978-01-23 1984-06-13 Efamol Ltd Pharmaceutical and dietary composition comprising gamma-linolenic acids
HU204199B (en) * 1987-03-18 1991-12-30 Caola Kozmetikai Process for producing pharmaceutical compositions containing unsaturated fatty acids and selenium as active components
ES2032844T3 (en) * 1987-07-09 1993-03-01 Pierre Moreau NEW COMPOSITIONS RICH IN OLIGOELEMENTS AND ITS MANUFACTURING PROCEDURES.

Also Published As

Publication number Publication date
IE910050A1 (en) 1991-07-31
DK0440341T3 (en) 1994-02-14
HK74994A (en) 1994-08-05
EP0440341A1 (en) 1991-08-07
NZ236744A (en) 1993-03-26
DE69100724D1 (en) 1994-01-20
US5116624A (en) 1992-05-26
ZA91183B (en) 1991-10-30
EP0440341B1 (en) 1993-12-08
CA2033823A1 (en) 1991-07-19
ES2060290T3 (en) 1994-11-16
GB9001121D0 (en) 1990-03-21
CA2033823C (en) 2002-04-09
DE69100724T2 (en) 1994-04-28
IE67622B1 (en) 1996-04-17
JP3008213B2 (en) 2000-02-14
AU638525B2 (en) 1993-07-01
JPH0733655A (en) 1995-02-03
AU6925691A (en) 1991-07-25

Similar Documents

Publication Publication Date Title
ATE98125T1 (en) COMPOSITIONS OF ESSENTIAL FATTY ACIDS AND THERAPY.
GB8319073D0 (en) Fatty acid compositions
ATE72988T1 (en) FATTY ACID COMPOSITIONS.
AU4466693A (en) Fatty acid treatment
IL64885A (en) 3,20-dioxo-1,4-pregnadiene-17alpha-ol-17-aromatic heterocyclic esters,their preparation and pharmaceutical compositions containing them
NO924474D0 (en) ORAL PREPARATIONS WITH IMPROVED DETACHING EFFECT
ES2053990T3 (en) COMPOSITIONS OF ESSENTIAL FATTY ACIDS.
DE3875286D1 (en) ESSENTIAL FATTY ACID COMPOSITIONS.
AU633714B2 (en) New uses of l-deprenyl and compositions for same
ATE120730T1 (en) 3.3'-DITHIOBIS (PROPIONIC ACIDS) AND ESTERS THEREOF.
NO932984D0 (en) fatty TREATMENT
DE3484606D1 (en) Deodorant.
IT1248998B (en) COMPOSITION OF RUBBER TO BE CHEWED FOR THE PREVENTION AND TREATMENT OF DENTAL PLATE
FI863079A0 (en) KONTINUERLIGT FRIGOERANDE FENYLETANOLAMINDERIVATKOMPOSITIONER.
FR2691360B1 (en) PHARMACEUTICAL COMPOSITIONS PARTICULARLY FOR THE TREATMENT OF PERIODONTAL POCKETS AND METHOD OF MANUFACTURE.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee